## Supplemental Table S1 | Sequences of sgRNA and primers.

Code of the specific primers (LL0xx or RBxx), target genes, purpose and sequence (in 5'- 3' direction) with forward oligo (F) and reverse oligo (R).

Code	Gene	Purpose	Sequence $(5' \rightarrow 3')$
LL030	-	Constant R oligo	AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGA CTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC
LL031	Gba1	Target 1 sgRNA F	GCGTAATACGACTCACTATAGGAATAATCACCACAGCAAGG TTTTAGAGCTAGAAATAGC
LL039	Gba2	Target 2 sgRNA F	GCGTAATACGACTCACTATAGGCGGAGGGAGCATCACTCGG TTTTAGAGCTAGAAATAGC
LL042	Gba2	HRM F	GTATGTGTTGTTTTTTCAGGC
LL043	Gba2	HRM R	GCAATAACGGTTTTGTAGTGG
LL044	Gba1	HRM F	AGTCTCATCGGCAGGATGAG
LL045	Gba1	HRM R	CACTTGGACAGAAAGGTAAATC
LL023	Gba1	Sequencing F	CATTGCCATTTTCGTTTTTAGG
LL007	Gba1	Sequencing R	GGAACTGTCCTTGACTCTCCAT
LL036	Gba2	Sequencing F	AATGGTGGTACCGAAAGACC
LL037	Gba2	Sequencing R	AGTACTACAGACTTCATCTGC
RB485	h <i>GBA1</i>	h <i>GBA</i> F (Gateway cloning)	GGGGACAAGTTTGTACAAAAAAGCAGGCTccACCACCATGG AGTTTTCAAGTCCTTCC
RB487	hGBA1	h <i>GBA</i> R (Gateway cloning)	GGGGACCACTTTGTACAAGAAAGCTGGGTTCATCACTGGCG ACGCCACAGGTA

## Supplemental Table S2 | Overview of glycosphingolipid abnormalities in different Gba1-, Gba2and Gba1:Gba2 deficient animal models.

Differences in GlcSph, GlcCer and GlcChol in tissues from human patients (Hu) and published GD models including zebrafish (Zf) and mouse (Ms). Mx1-Cre<sup>+</sup>: Gba1 deficiency in the white blood cell lineage, Limp2: transporter of GBA1 to lysosomes, Npc1: exporter of cholesterol from lysosomes; a defect leads to accumulation of cholesterol and glycosphingolipids.

-: no significant increase or reduction, nd: not determined

		Animal, organ	GlcSph	GlcCer	GlcChol	Reference
Gba1						
	Gaucher disease	Hu: plasma	$\uparrow\uparrow\uparrow$	$\uparrow$	$\uparrow$	(27, 58)
	Gba1 deficient (inhibitor <b>3</b> )	Zf: larvae	个个	$\uparrow$	$\uparrow$	This publication
	<i>Gba1<sup>-/-</sup></i> (Full KO)	Zf: larvae Zf: brain	ተተ ተተተ	$\uparrow \\ \uparrow \uparrow$	nd nd	(38)
	Mx1–Cre <sup>+</sup> :GD1	Ms: spleen, Ms: liver	ተተተ ተተ	个 个	个 个	(18, 27, 71)
	Limp2 <sup>-/-</sup>	Ms: spleen, Ms: liver	↑ ↑	-	nd ↑	(27, 71)
	Npc1 <sup>-/-</sup>	Ms: spleen, Ms: liver	ተተ ተተ	↑ ↑	nd ↑	(71)
Gba2						
	Gba2 KO	Zf: larvae	-	$\uparrow$	$\downarrow$	This publication
	Gba2 <sup>-/-</sup>	Ms: spleen Ms: liver Ms: testis	- - nd	个 个 个	↓ ↓ nd	(18, 27, 67, 72)
Gba1:Gba2						
	Gba1:Gba2 KO	Zf: larvae	个个	$\uparrow$	$\downarrow$	This publication

Mx1-Cre <sup>+</sup> :GD1: $Gba2^{-/-}$	Ms: spleen Ms: liver	个个 nd	个 个	nd nd	(18)
Npc <sup>-/-</sup> :Gba2 <sup>-/-</sup>	Ms: brain	$\uparrow\uparrow$	$\uparrow$	nd	(28)



Supplemental Figure S1 | ABP, Coomassie gels and western blot of figures 1D, 1E and 1F.



Supplemental Figure S2 | Photos of females (left) and males (right) of WT (A), gba1<sup>+/-</sup> (B), gba2<sup>-/-</sup>

(C) and  $gba1^{+/-}:gba2^{-/-}$  (D) adult zebrafish (9-12 months of age).



Supplemental Figure S3 | ABP, Coomassie gels and western blot of figures 2B, 3B and 4A.



Supplemental Figure S4  $\mid$  ABP, Coomassie gels of figures 5B (a) and duplo (b).

## HILIC separation - HexSph/ HexCer



**Supplemental Figure S5** | Elution patterns of HexSph or deacylated HexCer using HILIC separation. A) Elution profile of an equimolar mixture of glucosylceramide and galactosylceramide after microwave-assisted saponification, with deacylated GlcCer (measured as GlcSph) eluting at 5.20 min. and deacylated GalCer (measured as GalSph) eluting at 5.52 min. B) Elution profile of the upper phase separating GlcSph and GalSph of a GBA1 deficient (inhibitor **3** treated) sample. C). Elution profile of microwave-assisted deacylation of the lower phase separating deacylated GlcCer and GalCer (measured as GlcSph and GalSph respectively) of a WT sample.



**Supplemental Figure S6** (A) Schematic representation of the dissection of a zebrafish larvae into head and body. (B) Glycosphingolipid levels of dissected head and body regions of WT and gba1 KO larvae at 5dpf in pmol/ fish. Data is depicted as mean  $\pm$  SD and analysed using One-Way Anova (Dunnett's test) with wt as control group with \*\*\* *P* < 0.001 and \*\*\*\* *P* < 0.0001.



Supplemental Figure S7 | (Glyco)sphingolipids of gba1, gba2 and gba1:gba2 genotypes in

pmol/fish.



**Supplemental Figure S8** | Elution patterns of HexChol using HILIC separation. A) Elution profile of a mixture of GlcChol and GalChol (ratio of 4:1) and the <sup>13</sup>C-GlcChol internal standard. B) Elution profile of a WT sample. C) Levels of GlcChol and GalChol as determined by HILIC separation (while bar and striped bar respectively, n = 3) in pmol/ fish compared to HexChol as determined using standard methods (black bar; Figure 4B, n = 15) in pmol/ fish.



**Supplemental Figure S9** | (Glyco)sphingolipids of *gba1*, *gba2* and *gba1:gba2* embryos at different ages in pmol/fish



**Supplemental Figure S10** | Excreted GlcSph in egg water: control egg water (no incubation), pooled egg water of DMSO incubated zebrafish individuals (500  $\mu$ L, n = 5 individuals) and pooled egg water of inhibitor **3** incubated zebrafish individuals (500  $\mu$ L, n = 5 individuals). GlcSph is expressed in pmol/ egg water of 1 fish (100  $\mu$ L) and depicted as mean ± SD.



**Supplemental Figure S11** | (Glyco)sphingolipids in the different *gba1* and *gba2* genetic backgrounds treated with inhibitor **3** (10  $\mu$ M, grey bars) in pmol/fish.



**Supplemental Figure S12** (Glyco)sphingolipids of wild-type embryos incubated with 10  $\mu$ M inhibitor **3** in combination with different concentrations of AMP-DNM (striped bars), L- *ido*-AMP-DNM (broader striped bars) or Eliglustat (dotted bars) in pmol/fish.



**Supplemental Figure S13** | (Glyco)sphingolipids of wildtype embryos treated with different concentrations of AMP-DNM (striped bars), L-*ido*-AMP-DNM (broader striped bars) or Eliglustat (dotted bars) in pmol/fish.